Abstract:The CYP2A6 gene spans a region of approximately 6 kb pairs consisting of 9 exons and has been mapped to the long arm of chromosome 19 (between 19q12 and 19q13.2). The CYP2A6 protein has 494 amino acids and is an important hepatic Phase I enzyme that metabolizes approximately 3% of therapeutic drugs (n > 30; e.g. valproic acid, pilocarpine, tegafur, fadrozole, ifosfamide, cyclophosphamide, nicotine, tamoxifen, promazine, propofol, and cisapride), environmental toxicants (e.g. gasoline additives), and many procarcinogens such as nitrosamines and aflatoxin B(1). This enzyme also participates in the biotransformation of several endogenous compounds such as retinoid acids and steroids. Because CYP2A6 is responsible for 70-80% of the initial metabolism of nicotine, CYP2A6 has been proposed to be a novel target for smoking cessation. Site-directed mutagenesis and homology modeling studies have identified a number of amino acids (e.g. F300, A301, S208, S369, and L370) that play a role in substrate recognition and binding. CYP2A6 shows a crystal structure with a compact, hydrophobic active site with Asn297 serving as one hydrogen bond donor and orienting substrates for regio-selective oxidation. CYP2A6 contains the second smallest active site cavity among the human CYPs with known structures. The regulation mechanism of CYP2A6 expression is not fully understood, but available data suggest that several nuclear receptors including constitutive androstane receptor, pregnane X receptor and glucocorticoid receptor are involved in its regulation. Pilocarpine and tranylcypromine are commonly used as selective competitive inhibitors of CYP2A6. Selegiline, methoxsalen, (R)-(+) menthofuran and decursinol angelate are mechanism-based inhibitors of CYP2A6. Both in vitro and in vivo studies have demonstrated a wide (20- to >100-fold) interindividual variation in CYP2A6 expression and activity, which is due primarily to genetic polymorphisms in the CYP2A6 gene, but CYP2A6 activity is also modified by certain drugs and pathological and environmental factors. To date, more than 36 variant alleles (*1B through *37) of the CYP2A6 gene have been identified. There have been 278 SNPs found in the CYP2A6 upstream sequence, 8 introns and 9 exons in NCBI dbSNP. Polymorphism of CYP2A6 has been associated with smoking behavior, drug clearance and lung cancer risk. Further studies are warranted to explore the role of CYP2A6 in clinical practice, drug development and toxicology.

CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6-Mediated Drug Metabolism in Healthy Human Liver Tissue

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Search for an Association Between the Human CYP1A2 Genotype and CYP1A2 Metabolic Phenotype.

Correlation Between Cytochrome P-450cyp2d6 Cyp2d6) Genotype and Phenotype

The Cytochrome P450 2D6 (CYP2D6) Enzyme Polymorphism: Screening Costs and Influence on Clinical Outcomes in Psychiatry

Novel Independent Trans- and Cis-Genetic Variants Associated with CYP2D6 Expression and Activity in Human Livers.

Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.

Genetic Variability in CYP3A5 and Its Possible Consequences

Molecular mechanisms underlying single nucleotide polymorphism-induced reactivity decrease in CYP2D6

Expression Of Constitutive Androstane Receptor, Hepatic Nuclear Factor 4 Alpha, And P450 Oxidoreductase Genes Determines Interindividual Variability In Basal Expression And Activity Of A Broad Scope Of Xenobiotic Metabolism Genes In The Human Liver

Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6

Deep mutational scanning of CYP2C19 in human cells reveals a substrate specificity-abundance tradeoff

Evaluation of the Effects of 18 Non-Synonymous Single-Nucleotide Polymorphisms of CYP450 2C19 on in Vitro Drug Inhibition Potential by a Fluorescence-Based High-Throughput Assay.

Phenotype–Genotype Correlation Applying a Cocktail Approach and an Exome Chip Analysis Reveals Further Variants Contributing to Variation of Drug Metabolism

Cloning of CYP2J2 Gene and Identification of Functional Polymorphisms

Single Nucleotide Polymorphism of CYP3A4 Intron 2 and Its Influence on CYP3A4 Mrna Expression and Liver Enzymatic Activity in Human Liver

Characterization of 15 CYP2J2 variants identified in the Chinese Han population on the metabolism of ebastine and terfenadine in vitro

Functional Evaluation of Genetic and Environmental Regulators of P450 Mrna Levels.

CYP2J2*7 Single Nucleotide Polymorphism in a Chinese Population.

Polymorphisms of Human Cytochrome P450 2c9 and the Functional Relevance

Identification of CYP2D6 Impaired Functional Alleles in Mexican Americans.